| Added by | llasorsa |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer |
| Creator | Pujol et al. |
| Author | Jean-Louis Pujol |
| Author | Amandine Coffy |
| Author | Andrea Camerini |
| Author | Athanasios Kotsakis |
| Author | Manlio Mencoboni |
| Author | Milena Gusella |
| Author | Felice Pasini |
| Author | Aldo Pezzuto |
| Author | Giuseppe Luigi Banna |
| Author | Cemil Bilir |
| Author | Epaminontas Samantas |
| Author | Fabrice Barlesi |
| Author | Benoît Roch |
| Author | Aude Guillou |
| Abstract | INTRODUCTION: Several non-comparative phase II studies have evaluated metronomic oral vinorelbine (MOV) in metastatic non-small cell lung cancer (NSCLC) but the small size of each study limits their conclusions. PURPOSE: To perform an individual patient-data metaanalysis of studies evaluating MOV in metastatic NSCLC in order to measure survival and safety of treatment with this regimen. METHODS: Studies were selected if (1) administration of oral vinorelbine thrice a week; (2) fixed daily dose comprised between 30 and 50 mg, and; (3) being published before October 4th 2018. Database encompassed 8 variables characterizing disease and demography, 3 informing therapy, and 12 describing survival and toxicity. RESULTS: Nine studies encompassing 418 patients fulfilled the selection criteria, 80% of them having frailty characteristics. Median overall survival (OS) was 8.7 months (95%CI: 7.6-9.5). OSrates at 6 months, one year and at two years after starting vinorelbine were 64%, 30.3% and 8.9%, respectively. In the Cox model, Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 2, and anemia of any grade were significant determinants of shorter OS. Median progression-free survival(PFS) was 4.2 months (95%CI: 3.9-5). At 6 months and at one-year, PFS rates were 35% and 11.9% respectively. In the Cox model stratified for the variable "study", PS = 2and stage IV were significant determinants of shorter PFS. No toxicity was reported for 40% of patients, and 66 (15.8%) patients experienced a grade 3-4 toxicity. The most frequent toxicity was anemia of any grade (35.8%) that was higher with the 50 mg dosage. CONCLUSION: MOV is an active and well-tolerated chemotherapy in metastatic NSCLC and is a manageable therapy in frail patients. |
| Publication | PloS One |
| Volume | 14 |
| Issue | 8 |
| Pages | e0220988 |
| Date | 2019 |
| Journal Abbr | PLoS One |
| Language | eng |
| DOI | 10.1371/journal.pone.0220988 |
| ISSN | 1932-6203 |
| Library Catalog | PubMed |
| Extra | PMID: 31430345 PMCID: PMC6701879 |
| Tags | Administration, Metronomic, Administration, Oral, Anemia, Antineoplastic Agents, Phytogenic, Carcinoma, Non-Small-Cell Lung, Clinical Trials, Phase II as Topic, Humans, Lung Neoplasms, Progression-Free Survival, Time Factors, Vinorelbine |
| Date Added | 2022/09/29 - 15:09:25 |
| Date Modified | 2022/09/29 - 15:09:25 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
